asciminib
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Pressure score
75
Momentum score
51
Why This Matters
Lilly is a regulatory competitive threat because recent agency-facing activity on asciminib in Hematology · Chronic Myeloid Leukemia may reset approval benchmarks and timeline expectations for Novartis.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Approved
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Approved competitor status elevates immediate revenue and share risk.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Lilly's asciminib directly references the same indication focus (Hematology · Chronic Myeloid Leukemia) as this signal.
Source: Lilly
View source documentRelated Signal
Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 3
Lilly
1 competitive finding
Top program: asciminib
- Pressure
- 75
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
75LillyHighasciminib·Approved
Bristol Myers Squibb
1 competitive finding
Top program: asciminib
- Pressure
- 58
- Momentum
- 14
- Threat
- emerging competitor
- Stage
- Phase I
58Bristol Myers SquibbMediumasciminib·Phase I
Roche
2 competitive findings
Top program: asciminib
- Pressure
- 55
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
55RocheMediumasciminib·Approved